Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02809092|
Recruitment Status : Recruiting
First Posted : June 22, 2016
Last Update Posted : November 27, 2017
Relapsed acute myeloblastic leukemia (AML) requires remission prior to allogeneic Hematopoietic Stem Cell Transplant (HSCT) for optimal survival, but is a disease with poor response to chemotherapy. Human leukocyte antigen (HLA) haploidentical, Natural killer (NK) enriched peripheral blood cell infusions have shown safety in patients with poor prognosis AML. Though not powered for such an assessment, this trial showed a promising but not statistically significant trend in remission rate. NK cell therapy was limited by small numbers of NK cells attainable through leukapheresis. We have now demonstrated that large numbers of NK cells can be propagated ex vivo from a small volume blood draw, obviating the need for donor leukapheresis. The purpose of this trial is to determine the feasibility and maximum tolerated dose of expanded NK cells and estimate the toxicity of treating relapsed/refractory AML with fludarabine + high-dose cytarabine + G-CSF (FLAG) chemotherapy followed by haploidentical expanded natural killer (NK) cells.
The first NK cell dosing cohort will be well below the currently-established safe dose of pheresis-derived NK cells, as expanded NK cells may have increased toxicity because of their activated phenotype. In order to avoid accruing patients at suboptimal doses, a dose escalation schema based on the principles of an accelerated titration design is used in this study to allow expeditious advancement up to the current safe dose of NK cells.
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Biological: NK Cells + Chemotherapy Starting||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21- Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia|
|Actual Study Start Date :||April 1, 2017|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||September 2020|
Experimental: NK Cells + Chemotherapy Starting
Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.
NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.
Biological: NK Cells + Chemotherapy Starting
Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.
Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.
Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.
Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.
Other Name: Natural killer cells
- Maximum Tolerated Dose (MTD) of membrane-bound interleukin 21 (mbIL21)-Expanded Haploidentical NK Cells After Induction Chemotherapy with Fludarabine, Cytarabine, and Granulocyte-colony stimulating factor (G-CSF). [ Time Frame: 28 days ]
Maximum tolerated dose defined as highest dose studied in which 6 patients have been treated and at most 2 patients with dose-limiting toxicities (DLTs) observed.
A dose-limiting toxicity (DLT) is defined as:
Acute severe (grade 3 or 4) infusional allergic reaction related to the NK cells infusion.
Prolonged cytopenia beyond D+28. If neutropenia is still present at day 28, that will trigger the designation of prolonged neutropenia as a DLT. If neutrophil counts have recovered by day 28, then no DLT will have occurred. In either case, the status of neutrophil recovery beyond day 28 will not change the designation of DLT or No DLT made at day 28.
Acute GvHD overall grade 3 or 4. Severe (grade 3 or 4) unexpected toxicity related to the NK cell infusion.
- Complete Remission (CR) Assessment Following Infusion of the NK Cells [ Time Frame: Baseline up to Day 56 ]Percentage of participants with complete remission (CR): Bone marrow aspiration - Less than 5% leukemic blasts. Disease assessment after neutrophil recovery and or Day 28, whichever is earlier: 1. Unilateral bone marrow biopsy and aspirate for cytology, flow cytometry, Minimal Residual Disease MRD, chimerism, cytogenetics, and fluorescent in situ hybridization (FISH) (for known tumor markers). 2. If recovery has not occurred by Day +28, then a second bone marrow will be obtained at the time of neutrophil recovery or Day +56, whichever is earlier. CR estimated with Kaplan-Meier estimator and tabulated with 95% confidence intervals.
- Donor NK-Cell Expansion [ Time Frame: 28 days ]Donor NK-cell expansion defined as an absolute circulating donor-derived NK cell count that increases above the post-infusion level. Proportion of patients with successful in vivo NK-cell expansion estimated with a 95% confidence interval. The following chimerism methods employed to determine origin and number of circulating NK cells. Chimerism may be determined by flow cytometry using haplotype-specific antibodies. Chimerism may be determined by short tandem repeat (STR) polymorphisms. When there is a sex-mismatch between the donor and the recipient, assays based on determining the frequency of sex-chromosomes may be used.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02809092
|Contact: Lucia Silla, Doctoremail@example.com|
|Contact: Vanessa Valim, Mscfirstname.lastname@example.org|
|Centro Terapia e Tecnologia Celular||Recruiting|
|Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903|
|Contact: Lucia Silla, PhD 55 51 33597516 email@example.com|
|Contact: Vanessa Valim, Msc 55 51 33598850 firstname.lastname@example.org|
|Principal Investigator:||Lucia Silla, Doctor||Hospital de Clinicas de Porto Alegre|